Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DSNKY Daiichi Sankyo	$15.10 -6.6%	$17.36	$15.10 ▼ $27.50	$28.60B	-0.16	431,327 shs	232,748 shs
LLY Eli Lilly and Company	$1,081.34 +1.6%	$959.18	$623.78 ▼ $1,149.10	$1.02T	0.53	3.19 million shs	2.65 million shs
MRK Merck & Co., Inc.	$114.92 -0.6%	$116.42	$76.66 ▼ $125.14	$283.84B	0.21	10.83 million shs	8.22 million shs
NVO Novo Nordisk A/S	$42.06 -2.0%	$41.12	$35.12 ▼ $81.44	$187.78B	0.78	20.66 million shs	11.29 million shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DSNKY Daiichi Sankyo	-1.16%	-4.43%	-2.30%	-12.07%	-40.55%
LLY Eli Lilly and Company	-1.43%	-0.21%	+10.29%	+6.02%	+42.58%
MRK Merck & Co., Inc.	+0.53%	-3.22%	+3.20%	-3.72%	+52.04%
NVO Novo Nordisk A/S	-2.46%	-3.00%	-2.08%	+11.49%	-41.01%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DSNKY Daiichi Sankyo	$15.10 -6.6%	$17.36	$15.10 ▼ $27.50	$28.60B	-0.16	431,327 shs	232,748 shs
LLY Eli Lilly and Company	$1,081.34 +1.6%	$959.18	$623.78 ▼ $1,149.10	$1.02T	0.53	3.19 million shs	2.65 million shs
MRK Merck & Co., Inc.	$114.92 -0.6%	$116.42	$76.66 ▼ $125.14	$283.84B	0.21	10.83 million shs	8.22 million shs
NVO Novo Nordisk A/S	$42.06 -2.0%	$41.12	$35.12 ▼ $81.44	$187.78B	0.78	20.66 million shs	11.29 million shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DSNKY Daiichi Sankyo	-1.16%	-4.43%	-2.30%	-12.07%	-40.55%
LLY Eli Lilly and Company	-1.43%	-0.21%	+10.29%	+6.02%	+42.58%
MRK Merck & Co., Inc.	+0.53%	-3.22%	+3.20%	-3.72%	+52.04%
NVO Novo Nordisk A/S	-2.46%	-3.00%	-2.08%	+11.49%	-41.01%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DSNKY Daiichi Sankyo	3.00	Buy	N/A	N/A
LLY Eli Lilly and Company	2.87	Moderate Buy	$1,227.00	13.47% Upside
MRK Merck & Co., Inc.	2.68	Moderate Buy	$128.18	11.53% Upside
NVO Novo Nordisk A/S	2.13	Hold	$65.56	55.90% Upside

Current Analyst Ratings Breakdown

Latest LLY, NVO, DSNKY, and MRK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/26/2026	LLY Eli Lilly and Company	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$1,133.00 ➝ $1,251.00
5/26/2026	LLY Eli Lilly and Company	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$1,119.00
5/22/2026	LLY Eli Lilly and Company	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$1,283.00
5/21/2026	LLY Eli Lilly and Company	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$1,350.00
5/21/2026	LLY Eli Lilly and Company	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform
5/21/2026	LLY Eli Lilly and Company	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target		$1,300.00 ➝ $1,330.00
5/19/2026	LLY Eli Lilly and Company	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy (B) ➝ Buy (B-)
5/15/2026	MRK Merck & Co., Inc.	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C+) ➝ Hold (C)
5/12/2026	NVO Novo Nordisk A/S	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
5/7/2026	LLY Eli Lilly and Company	Rothschild & Co Redburn Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target		$880.00 ➝ $900.00
5/6/2026	MRK Merck & Co., Inc.	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Neutral	$125.00

(Data available from 6/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DSNKY Daiichi Sankyo	$14.10B	2.03	$1.16 per share	13.03	$5.61 per share	2.69
LLY Eli Lilly and Company	$72.25B	14.09	$25.12 per share	43.05	$28.07 per share	38.52
MRK Merck & Co., Inc.	$65.01B	4.37	$11.40 per share	10.08	$21.22 per share	5.42
NVO Novo Nordisk A/S	$46.80B	4.01	$4.47 per share	9.40	$6.58 per share	6.39

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DSNKY Daiichi Sankyo	$1.73B	$0.94	16.06	12.80	1.17	12.32%	15.74%	7.11%	7/30/2026 (Estimated)
LLY Eli Lilly and Company	$20.64B	$28.15	38.41	24.39	1.18	34.98%	105.77%	23.76%	8/5/2026 (Estimated)
MRK Merck & Co., Inc.	$18.25B	$3.55	32.37	11.75	2.59	13.59%	27.55%	10.73%	8/4/2026 (Estimated)
NVO Novo Nordisk A/S	$15.51B	$4.26	9.87	12.23	3.93	37.23%	63.31%	22.19%	8/5/2026 (Estimated)

Latest LLY, NVO, DSNKY, and MRK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/11/2026	Q4 2026	DSNKY Daiichi Sankyo	$0.3317	$0.15	-$0.1817	$0.15	$3.74 billion	$3.76 billion
5/6/2026	Q1 2026	NVO Novo Nordisk A/S	$0.87	$1.04	+$0.17	$1.69	$10.86 billion	$10.85 billion
4/30/2026	Q1 2026	LLY Eli Lilly and Company	$6.97	$8.55	+$1.58	$8.26	$17.82 billion	$19.80 billion
4/30/2026	Q1 2026	MRK Merck & Co., Inc.	-$1.47	-$1.28	+$0.19	-$1.72	$15.85 billion	$16.29 billion
3/31/2026	Q1 2026	NVO Novo Nordisk A/S	N/A	$1.0270	N/A	$1.69	N/A	$10.85 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
DSNKY Daiichi Sankyo	$0.18	1.19%	N/A	19.15%	N/A
LLY Eli Lilly and Company	$6.92	0.64%	+15.18%	24.58%	11 Years
MRK Merck & Co., Inc.	$3.40	2.96%	+5.75%	95.77%	14 Years
NVO Novo Nordisk A/S	$1.75	4.16%	+21.74%	41.08%	N/A

Latest LLY, NVO, DSNKY, and MRK Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/26/2026	MRK Merck & Co., Inc.	quarterly	$0.85	2.84%	6/15/2026	6/15/2026	7/8/2026
5/4/2026	LLY Eli Lilly and Company	quarterly	$1.73	0.69%	5/15/2026	5/15/2026	6/10/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DSNKY Daiichi Sankyo	0.18	2.69	1.85
LLY Eli Lilly and Company	1.26	1.50	1.10
MRK Merck & Co., Inc.	1.02	1.30	1.06
NVO Novo Nordisk A/S	0.59	0.79	0.56

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DSNKY Daiichi Sankyo	N/A
LLY Eli Lilly and Company	82.53%
MRK Merck & Co., Inc.	76.07%
NVO Novo Nordisk A/S	11.54%

Insider Ownership

Company	Insider Ownership
DSNKY Daiichi Sankyo	N/A
LLY Eli Lilly and Company	0.14%
MRK Merck & Co., Inc.	0.17%
NVO Novo Nordisk A/S	0.07%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DSNKY Daiichi Sankyo	17,435	1.89 billion	N/A	Not Optionable
LLY Eli Lilly and Company	50,000	941.74 million	940.42 million	Optionable
MRK Merck & Co., Inc.	75,000	2.47 billion	2.47 billion	Optionable
NVO Novo Nordisk A/S	69,505	4.47 billion	4.46 billion	Optionable

LLY, NVO, DSNKY, and MRK Headlines

Recent News About These Companies

Novo Nordisk launches Wegovy pill in UAE, its first global market

4 hours ago | qz.comQ

European Stocks Close Lower; PMI Signals Possible Q2 Contraction

4 hours ago | finance.yahoo.com

Novo Nordisk is taking its Wegovy pill beyond the U.S.

4 hours ago | finance.yahoo.com

Novo Nordisk is taking its Wegovy pill beyond the U.S.

June 3 at 12:04 PM | gurufocus.com

5 Stocks Set to Cash in on The Next 90-Million Customer Industry. (It's Not AI)

June 3 at 8:38 AM | 247wallst.com

Wall Street Breakfast Podcast: Bitcoin's Great Withdrawal

June 3 at 7:01 AM | seekingalpha.com

Natixis Advisors LLC Purchases 105,703 Shares of Novo Nordisk A/S $NVO

June 3 at 5:59 AM | marketbeat.com

Novo Nordisk A/S $NVO Stock Position Decreased by Peapack Gladstone Financial Corp

June 3 at 5:42 AM | marketbeat.com

Novo Nordisk launches Wegovy in UAE

June 3 at 4:33 AM | reuters.com

Novo Nordisk rolls out Wegovy pill in the UAE — its first market outside the U.S.

June 3 at 3:42 AM | cnbc.com

Novo Nordisk Launches Wegovy Weight-Loss Pill in UAE

June 3 at 3:03 AM | wsj.com

Wegovy® pill launches in the UAE as Novo Nordisk expands global access to obesity care

June 3 at 2:00 AM | globenewswire.com

Novo Exports Help Danish Economy Outpace Europe, Danske Says

June 2 at 12:30 AM | financialpost.comF

Is Novo Nordisk A/S (NVO) Expanding Its Lead in Diabetes and Weight Loss Ahead of ADA Conference?

June 2 at 3:17 PM | finance.yahoo.com

Eli Lilly Wins Back CVS Health, Reverting Novo's Advantage (NVO)

...

June 2 at 11:15 AM | marketbeat.com

Novo Nordisk's Wegovy Pill to Launch in the UAE Following Regulatory Approval

June 2 at 10:15 AM | marketwatch.com

NOVI Health Partners with Novo Nordisk to Expand Access to Structured Weight Care Support in Singapore

June 2 at 10:15 AM | finance.yahoo.com

Pfizer's Obesity and Oncology Pipeline Sets Up a Catalyst-Rich 2026

June 2 at 10:15 AM | finance.yahoo.com

5 Best Growth Stocks for the Next 10 Years (NVO)

...

June 1 at 10:15 AM | marketbeat.com

Wegovy pill maintains GLP-1 lead over Lilly rival, but weekly growth slows

June 1 at 8:59 AM | proactiveinvestors.co.uk

Is Eli Lilly Starting an Nvidia-Style Run?

June 1 at 7:35 AM | fool.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

LLY, NVO, DSNKY, and MRK Company Descriptions

Daiichi Sankyo OTCMKTS:DSNKY

$15.10 -1.07 (-6.62%)

As of 04:00 PM Eastern

Daiichi Sankyo Company, Limited manufactures, markets, and sells pharmaceutical products worldwide. The company offers Enhertu, a HER2 directed antibody drug conjugate; Turalio, a CSF-1R inhibitor; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia; ferric carboxymaltose injection for treating anaemia; and Injectafer for the treatment for iron deficiency anaemia. It also provides olmesartan medoxomil antihypertensive agents; NILEMDO, an oral treatment to help in lowering cholesterol; and Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe for reducing cholesterol. In addition, the company offers Canalia for the treatment of type 2 diabetes mellitus; Emgalty for the treatment of migraine attacks; Pralia for the treatment of anti-osteoporosis/inhibitor of the progression of bone erosion associated with rheumatoid arthritis; Ranmark for the treatment of bone complications caused by bone metastasis from tumors; Tarlige for treating pain; Tenelia for the treatment of Type 2 diabetes mellitus; Venofer for the treatment of iron deficiency anemia; and Vimpat, an anti-epileptic agent. Further, it provides vaccines for influenza, measles/rubella infection, and mumps. The company has a development and commercialization agreement with Merck to jointly develop and commercialize Daiichi Sankyo's DXd antibody drug conjugate (ADC) candidates The company was founded in 1899 and is headquartered in Tokyo, Japan.

Eli Lilly and Company NYSE:LLY

$1,081.34 +17.19 (+1.62%)

Closing price 03:58 PM Eastern

Extended Trading

$1,077.00 -4.34 (-0.40%)

As of 05:37 PM Eastern

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Merck & Co., Inc. NYSE:MRK

$114.92 -0.73 (-0.63%)

Closing price 03:58 PM Eastern

Extended Trading

$115.12 +0.20 (+0.17%)

As of 05:35 PM Eastern

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Novo Nordisk A/S NYSE:NVO

$42.06 -0.87 (-2.02%)

Closing price 03:58 PM Eastern

Extended Trading

$41.99 -0.06 (-0.15%)

As of 05:37 PM Eastern

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LLY, NVO, DSNKY, and MRK Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LLY, NVO, DSNKY, and MRK Earnings

Compare Dividends

Latest LLY, NVO, DSNKY, and MRK Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LLY, NVO, DSNKY, and MRK Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

LLY, NVO, DSNKY, and MRK Company Descriptions

Daiichi Sankyo OTCMKTS:DSNKY

Eli Lilly and Company NYSE:LLY

Merck & Co., Inc. NYSE:MRK

Novo Nordisk A/S NYSE:NVO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools